Join Now

Category Archives: BioUtah News

Owlet® Strengthens Market Leadership as Dream Sight™ Becomes the First Baby Monitor Awarded the SGS Cybersecurity Mark

By Natalie Themm | Published October 30, 2025

Earning the first-ever SGS Cybersecurity Mark in the baby monitor category, Owlet reinforces its leadership in safety, security, privacy, and innovation.

| Tagged | Comments Off on Owlet® Strengthens Market Leadership as Dream Sight™ Becomes the First Baby Monitor Awarded the SGS Cybersecurity Mark

Co-Diagnostics Signs Definitive Agreement with Arabian Eagle in the Kingdom of Saudi Arabia to Establish CoMira Diagnostics and Localize Co-Dx™ PCR Platform Across the Middle East

By Natalie Themm | Published October 30, 2025

The new Saudi-based CoMira Diagnostics joint venture will be engaged in manufacturing and distribution of the Company’s upcoming Co-Dx™ PCR platform and other Co-Dx IP across KSA and 18 other MENA countries

| Tagged | Comments Off on Co-Diagnostics Signs Definitive Agreement with Arabian Eagle in the Kingdom of Saudi Arabia to Establish CoMira Diagnostics and Localize Co-Dx™ PCR Platform Across the Middle East

EDWARDS SAPIEN 3 TAVR DELIVERS PROVEN LONG-TERM BENEFITS AND VALVE PERFORMANCE, NEW DATA PRESENTED AT TCT 2025

By Natalie Themm | Published October 30, 2025

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years

| Tagged | Comments Off on EDWARDS SAPIEN 3 TAVR DELIVERS PROVEN LONG-TERM BENEFITS AND VALVE PERFORMANCE, NEW DATA PRESENTED AT TCT 2025

SUCCESSFUL PATIENT OUTCOMES DEMONSTRATED WITH EDWARDS’ SAPIEN M3 AND EVOQUE SYSTEMS, NEW DATA PRESENTED AT TCT 2025

By Natalie Themm | Published October 30, 2025

ENCIRCLE mitral trial achieves primary and secondary endpoints.

| Tagged | Comments Off on SUCCESSFUL PATIENT OUTCOMES DEMONSTRATED WITH EDWARDS’ SAPIEN M3 AND EVOQUE SYSTEMS, NEW DATA PRESENTED AT TCT 2025

DiscGenics and Collaborators Announce Breakthrough in Tissue-Engineered Intervertebral Disc Research

By Natalie Themm | Published October 30, 2025

DiscGenics and Collaborators Announce Breakthrough in Tissue-Engineered Intervertebral Disc Research

| Tagged | Comments Off on DiscGenics and Collaborators Announce Breakthrough in Tissue-Engineered Intervertebral Disc Research

BioUtah Life Sciences Delegation Showcases Utah Innovation in Australia

By admin | Published October 23, 2025

As part of Governor Spencer Cox’s Australia Trade Mission from October 19–25, BioUtah led a focused Life Sciences Track highlighting Utah’s growing global leadership in biotechnology, medtech, diagnostics, and health innovation. The delegation met with prominent Australian partners, investors, and regulators to explore opportunities for collaboration and market expansion. Companies participating in the trade mission […]

| Comments Off on BioUtah Life Sciences Delegation Showcases Utah Innovation in Australia

Seek Labs Expands Global Disease Atlas to Include Hemorrhagic Fever Viruses

By admin | Published October 23, 2025

    Salt Lake City, Utah – October 21, 2025 Salt Lake City-based biotech firm Seek Labs announced today that it has expanded its Global Disease Atlas™ to include several of the world’s deadliest hemorrhagic fever viruses (HFVs) — namely, Ebola virus, Marburg virus, Lassa virus, Hantavirus, Crimean‑Congo hemorrhagic fever virus (CCHFV), and Rift Valley fever virus (RVFV). In July, the company announced that it […]

| Comments Off on Seek Labs Expands Global Disease Atlas to Include Hemorrhagic Fever Viruses

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

By admin | Published October 23, 2025

LEHI, Utah, Oct. 23, 2025 /PRNewswire/ — Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes of inflammation-driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational medicine ofirnoflast (HT-6184) for the treatment of Myelodysplastic Syndromes (MDS) — a group […]

| Comments Off on Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

 Journal of Clinical Microbiology Publishes Article on ARUP’s Validation of AI for Parasite Detection 

By admin | Published October 23, 2025

SALT LAKE CITY, October 21, 2025— ARUP Laboratories today announced the publication of an article in the Journal of Clinical Microbiology describing the company’s validation of a deep convolutional neural network (CNN) to detect parasites in concentrated wet mounts of stool.  For decades, detection of gastrointestinal parasites has relied on traditional microscopy, which is a […]

| Comments Off on  Journal of Clinical Microbiology Publishes Article on ARUP’s Validation of AI for Parasite Detection 

SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System

By admin | Published October 23, 2025

SALT LAKE CITY, Utah, Oct. 20, 2025 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramics specializing in biomedical applications of silicon nitride (Si₃N₄), today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the SINAPTIC® Foot & Ankle Osteotomy Wedge System, enabling SINTX’s commercial entry […]

| Comments Off on SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

By Natalie Themm | Published October 16, 2025

The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations

| Tagged | Comments Off on Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

bioMérieux invests in Allergen Alert, a startup resulting from its intrapreneurship program

By Natalie Themm | Published October 16, 2025

bioMérieux has just acquired a stake in Allergen Alert, an innovative startup specializing in the rapid detection of food allergens for individuals and professionals.

| Tagged | Comments Off on bioMérieux invests in Allergen Alert, a startup resulting from its intrapreneurship program

A Special Thanks To Our Legacy and Platinum Elite Members